You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Ultra-sensitive Rapid Diagnostic Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    Project SummaryAbstract Lymphatic filariasisLFcaused by the parasitic filarial worm Wuchereria bancroftiis a disfiguring and debilitating neglected tropical disease that affectsmillion people incountriesThrough the World Health Organization sWHOGlobal Program for the Elimination of Lymphatic FilariasisGPELFbillion drug regimens have been distributed via mass drug administrationMDAtomillion people ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based

    SBC: KLEIN BUENDEL, INC            Topic: 102

    Project Summary While studies support the efficacy of comprehensiveschool wide interventions in reducing bullyingthese types of programs can require significant time and financial resources for implementationresulting in barriers to providing school based bullying preventionespecially in low income and rural communitiesAdditionallyalthough training bystanders to act asdefenderson behalf of targets ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. The Point Digit: A ratcheting prosthetic finger using advanced rapid manufacturing technology

    SBC: POINT DESIGNS, LLC            Topic: NICHD

    The Point DigitA Ratcheting Prosthetic Finger UsingAdvanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop and commercialize a purely mechanicalratcheting prosthetic fingerthe Point Digitwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s metacar ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. The first commercial rapid diagnostic test to detect Paragonimus infections

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    Abstract We propose an ultrasensitive rapid diagnostic testRDTto detect exposure to pulmonary flukes of the genus ParagonimusParagonimiasis affects an estimatedmi l l ion people and remains amongst the most neglected of all neglected tropical diseasesNTDsThis trematode is acquired upon ingestion of raw or undercooked freshwater crustaceans and migrates to the lungs where it forms cystsTreatment is ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. The Development of TLR Antagonists for Therapy of Hepatic Fibrosis and Cirrhosis

    SBC: DYNAVAX TECHNOLOGIES CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): Hepatic fibrosis (HF) is a major health problem leading to cirrhosis and death. There is currently no pharmacological treatment for HF, and liver transplantation is unable to meet the needs of all patients afflicted with HF. We have shown that chronic liver injury involves the activation of Toll-like receptor 7 (TLR7) and TLR9. We further demonstrated that the ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. The Antibody Registry: A Community Authority for Antibody Research Resource Identifiers

    SBC: SCICRUNCH            Topic: 300

    Project SummaryOne of the most glaring yet easily addressable gaps in our current scientific workflow and publication system is improving the way that methods are reportedin particularthe lack of key methodological details necessary for interpreting and reproducing a studyMost authors continue to cite the name of the reagentlike an antibody using the vendorand the city where the vendor is locatedb ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Technology Transfer of the ATLAS and ATHENA Programs

    SBC: Odyssey Science Innovations, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): Over 7.5 million high school students participate in high school sports programs and an additional 2 million students join these athletic teams each year. Adolescent athletes are at risk for using performance enhancing drugs, such as anabolic steroids, unregulated sport supplements, and illicit drugs and alcohol. Unfortunately, few evidence-based substance abus ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government